Overview
Also known as:
FDA & Trial Timeline
2 eventsFondazione Policlinico Universitario Agostino Gemelli IRCCS
H. Lee Moffitt Cancer Center and Research Institute — PHASE1
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
4 availableAmtagvi
AMTAGVI is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and …
AMTAGVI is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor.
Braftovi
in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-authorized test
Opdualag
indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma
Zelboraf
ZELBORAF is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Financial Resources
1 resourcesTravel Grants
No travel grants are currently matched to Conjunctival malignant melanoma.
Community
No community posts yet. Be the first to share your experience with Conjunctival malignant melanoma.
Start the conversation →Latest news about Conjunctival malignant melanoma
Disease timeline:
New recruiting trial: Sentinel Lymph Node Biopsy in Ocular Surface and Adnexal Cancers
A new clinical trial is recruiting patients for Conjunctival malignant melanoma
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Conjunctival malignant melanoma
Are there clinical trials for Conjunctival malignant melanoma?
Yes — 2 recruiting clinical trials are currently listed for Conjunctival malignant melanoma on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.
Which specialists treat Conjunctival malignant melanoma?
13 specialists and care centers treating Conjunctival malignant melanoma are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.
What treatment and support options exist for Conjunctival malignant melanoma?
1 patient support program are currently tracked on UniteRare for Conjunctival malignant melanoma. See the treatments and support programs sections for copay assistance, eligibility, and contact details.